We serve Endo-3-Amine-9-Methyl-9-Azabicyclo[3,3,1]Nonane CAS:76272-56-5 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name: Endo-3-Amine-9-Methyl-9-Azabicyclo[3,3,1]Nonane
CAS.NO:76272-56-5
Synonyms:
9-Azabicyclo[3.3.1]nonan-3-amine, 9-methyl-
(3-endo)-9-Methyl-9-azabicyclo[3.3.1]nonan-3-amine
9-Azabicyclo[3.3.1]nonan-3-amine, 9-methyl-, (3-endo)
9-Methyl-9-azabicyclo[3.3.1]nonan-3-amine
Molecular Formula: C9H18N2
Molecular Weight:154.25300
Physical and Chemical Properties:
Density: 0.968 g / cm3
Boiling point: 115-119ºC (18 mmHg)
Melting point: 72.1ºC
Flash point: 67.3ºC
Refractive index: 1.517
Specification:
Appearance:Colorless or yellowish transparent liquid
Purity:≥98.5%
Water:≤1.0%
Oxime:≤0.2%
Individual impurities:≤0.5%
Total impurity:≤1.5%
Packing:
25kg cardboard drum or according to customer specified requirements
Storage:Stored in a cool and dry well-closed container. Keep away from moisture and strong light/heat.
Application:Intermediates of Granisetron hydrochloride CAS:107007-99-8
Contact us for information like Endo-3-Amine-9-Methyl-9-Azabicyclo[3,3,1]Nonane chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,9-Methyl-9-azabicyclo[3.3.1]nonan-3-amine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,9-Azabicyclo[3.3.1]nonan-3-amine, 9-methyl-, (3-endo) Use and application,9-Azabicyclo[3.3.1]nonan-3-amine, 9-methyl-, (3-endo) technical grade,usp/ep/jp grade.
Related News: Their pharmacological activity plays a direct role in the diagnosis, cure, mitigation, treatment, or prevention of disease.2-Bromo-3-methylbutyric acid manufacturer Their pharmacological activity plays a direct role in the diagnosis, cure, mitigation, treatment, or prevention of disease.5-Bromo-2-fluoro-4-methylbenzaldehyde supplier It is understood that at present, the industry competition for global characteristic APIs has shown a development trend of vertical integration, and the number of mergers and acquisitions between pharmaceutical manufacturers and API manufacturers is increasing.3-Bromo-6-hydroxy-2-methylpyridine vendor It is understood that at present, the industry competition for global characteristic APIs has shown a development trend of vertical integration, and the number of mergers and acquisitions between pharmaceutical manufacturers and API manufacturers is increasing.Catalent’s clinical supply network includes nine cGMP-certified clinical packaging facilities across North America, Europe and Asia, and more than 50 strategically-located depots around the world, providing local and regional options for clinical storage, distribution, expiry update and relabeling services, and clinical returns management.